1. Scrip
  2. >>Business

AbbVie Pinpoints US Humira Erosion At 37% In 2023

 
• By Joseph Haas

With adalimumab biosimilars now on market in the US, AbbVie said it expects sales erosion this year toward the lower end of its previous guidance, with pricing comprising the larger portion of the hit.

Biosimilar
With the first Humira biosimilar on the US market, AbbVie addressed investor concerns • Source: Shutterstock

Ten days after the first Humira biosimilar reached the US market, AbbVie Inc. is giving investors a definitive sense of what US revenue erosion will be for its top-seller in 2023 – 37% – with CEO Richard Gonzalez saying “the vast majority of that will be [from] price.”

Amgen, Inc. launched Amjevita, the first US Food and Drug Administration-approved biosimilar of adalimumab, on 31 January with two prices, discounted by 5% or 55% off of AbbVie’s wholesale acquisition cost for the anti-TNF biologic. (Also see "All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch" - Scrip, 1 February, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.